TRCT
MAZE

Tower Research Capital (TRC)’s Maze Therapeutics MAZE Stock Holding History

Tower Research Capital (TRC)’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.5K Sell
1,357
-1,421
-51% -$37.2K ﹤0.01% 2915
2026
Q1 		$82.9K Buy
2,778
+1,429
+106% +$63.1K ﹤0.01% 2338
2025
Q4 		$55.9K Sell
1,349
-663
-33% -$22.8K ﹤0.01% 2337
2025
Q3 		$52.2K Sell
2,012
-2,596
-56% -$43.8K ﹤0.01% 2500
2025
Q2 		$56.5K Buy
4,608
+3,774
+453% +$39.3K ﹤0.01% 2866
2025
Q1 		$9.18K Buy
+834
New +$10K ﹤0.01% 3813

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Tower Research Capital (TRC)'s MAZE Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Maze Therapeutics (MAZE) stake by 51% in Q2 2026, selling an estimated $37.2K and leaving 1,357 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2915.

Tower Research Capital (TRC) first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $82.9K in Q1 2026. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Tower Research Capital (TRC) held 1,357 shares of Maze Therapeutics worth $40.5K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,421 Maze Therapeutics shares in Q2 2026, an estimated $37.2K.
  • Maze Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2915 holding.
  • Tower Research Capital (TRC) first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Maze Therapeutics position peaked at $82.9K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.